Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(19 sites)
United States
Exelixis Clinical Site #4, Irvine, California Exelixis Clinical Site #19, Los Angeles, California Exelixis Clinical Site #10, Washington D.C., District of Columbia Exelixis Clinical Site #18, Orlando, Florida Exelixis Clinical Site #12, Atlanta, Georgia Exelixis Clinical Site #15, Chicago, Illinois Exelixis Clinical Site #5, St Louis, Missouri Exelixis Clinical Site #3, Huntersville, North Carolina Exelixis Clinical Site #6, Oklahoma City, Oklahoma Exelixis Clinical Site #9, Nashville, Tennessee Exelixis Clinical Site #1, Austin, Texas Exelixis Clinical Site #7, Dallas, Texas Exelixis Clinical Site #8, Houston, Texas Exelixis Clinical Site #11, Fairfax, Virginia Exelixis Clinical Site #2, Fairfax, Virginia United Kingdom
Exelixis Clinical Site #17, Leicester, England Exelixis Clinical Site #13, London, England Exelixis Clinical Site #16, London, England Exelixis Clinical Site #14, Manchester, England